AOD-9604 and Gabapentin Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Raises Questions

AOD-9604 is a modified fragment (amino acids 176-191) of human growth hormone, used in compounding pharmacy settings for adipose tissue modulation. Gabapentin, a gamma-aminobutyric acid (GABA) analog approved for postherpetic neuralgia and epilepsy, is one of the most frequently prescribed medications in the United States. In 2022, gabapentin ranked among the top 10 most dispensed drugs in the U.S., with over 69 million prescriptions filled according to ClinCalc data derived from IQVIA reporting. Given how commonly gabapentin is prescribed, patients exploring AOD-9604 for body composition goals will inevitably ask whether these two agents can coexist safely.

The short answer: no direct interaction study exists. That absence of data is itself clinically meaningful. AOD-9604 has never undergone the full drug-drug interaction (DDI) profiling that the FDA requires for new molecular entities. The FDA's 2020 guidance on DDI studies (Guidance for Industry: Clinical Drug Interaction Studies) specifies in vitro CYP inhibition/induction screening, P-glycoprotein assessment, and clinical pharmacokinetic studies as standard requirements [3]. AOD-9604 has bypassed this process entirely because it is supplied through 503A compounding rather than through the traditional NDA pathway.

Pharmacokinetic Analysis: Where These Agents Do and Do Not Overlap

The pharmacokinetic (PK) profiles of AOD-9604 and gabapentin suggest low interaction potential at the metabolic level, though renal clearance deserves attention.

AOD-9604 disposition. As a 16-amino-acid peptide, AOD-9604 undergoes proteolytic degradation rather than hepatic phase I or phase II metabolism. Peptides of this size are typically cleaved by circulating and tissue-bound peptidases into amino acid constituents. A 2014 study published in Obesity by Heffernan et al. examined AOD-9604 (also referred to as AOD9604) in obese subjects and confirmed oral bioavailability without hepatotoxicity signals, though detailed metabolic pathway mapping was not performed [4]. The compound does not interact with cytochrome P450 isoenzymes (CYP3A4, CYP2D6, CYP2C9, CYP1A2) based on its peptide structure and degradation pathway.

Gabapentin disposition. The FDA-approved gabapentin label states that gabapentin is not appreciably metabolized in humans [1]. The drug is eliminated unchanged by renal excretion with an elimination half-life of 5 to 7 hours. Gabapentin clearance is directly proportional to creatinine clearance. It is not bound to plasma proteins and does not inhibit or induce CYP enzymes [1].

Renal clearance overlap. Both agents produce metabolites or parent compound cleared through the kidneys. Gabapentin's renal dependence is well-characterized: the FDA label mandates dose reduction when creatinine clearance falls below 60 mL/min [1]. While AOD-9604's renal handling has not been formally studied, peptide fragments of this molecular weight (approximately 1,800 Da) are typically filtered at the glomerulus and may undergo tubular reabsorption or degradation. Competition for renal tubular transport is theoretically possible but unproven.

Pharmacodynamic Considerations: CNS Depression Risk

The more clinically relevant concern with this combination is pharmacodynamic, not pharmacokinetic.

Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing excitatory neurotransmitter release [5]. Its most common adverse effects are somnolence (19.3%), dizziness (17.1%), and ataxia (12.5%) per the prescribing information [1]. The FDA added a safety communication in December 2019 warning that gabapentinoids can cause respiratory depression, particularly when combined with other CNS depressants or in patients with underlying respiratory conditions [2].

AOD-9604's CNS profile is less established. Growth hormone itself crosses the blood-brain barrier and influences sleep architecture, cognitive function, and fatigue perception. A study by Nass et al. (2009) published in the Journal of Clinical Endocrinology and Metabolism demonstrated that GH-releasing peptides affect sleep EEG patterns and subjective alertness [6]. Whether the 176-191 fragment retains any of these neuroactive properties has not been isolated in controlled studies.

The practical concern is this: if a patient experiences drowsiness or dizziness from gabapentin (which roughly one in five patients does), adding any agent with even modest CNS activity could amplify those symptoms. Patients should be counseled to avoid driving or operating heavy machinery when initiating AOD-9604 while on stable gabapentin therapy until the combined effect on alertness is known.

What the DDI Databases Show

Major drug interaction databases, including Lexicomp, Micromedex, and Clinical Pharmacology, do not list AOD-9604 as a cataloged entity. This is typical for compounded peptides that lack an NDA or ANDA. The absence of a database entry does not mean the combination is safe. It means the combination has not been evaluated.

For comparison, the Endocrine Society's 2019 clinical practice guideline on growth hormone therapy in adults notes that recombinant human GH (somatropin) has documented interactions with glucocorticoids, insulin, oral estrogens, and CYP3A4 substrates [7]. The guideline, published in the Journal of Clinical Endocrinology and Metabolism, specifically states that "GH may increase the clearance of compounds metabolized by CYP3A4" [7]. AOD-9604 is a truncated, non-lipolytic fragment of GH and does not activate the GH receptor in the same manner as full-length somatropin. Whether it shares any of these CYP-modulating properties is unknown.

The American Association of Clinical Endocrinology (AACE) has not issued guidance on AOD-9604 specifically. Gabapentin interactions are well-cataloged: the drug has minimal PK interactions but meaningful PD interactions with opioids, benzodiazepines, and alcohol [1].

Renal Function: The Shared Variable

Both drugs converge on renal elimination, making kidney function the most important monitoring parameter for this combination.

Gabapentin dosing is strictly renal-adjusted. The FDA label specifies: 300 mg daily for CrCl 15-29 mL/min, 300 mg every other day for CrCl <15 mL/min, and a supplemental dose after each 4-hour hemodialysis session [1]. In patients with impaired renal function, gabapentin accumulates and CNS side effects intensify.

A 2021 population pharmacokinetic study by Zhu et al., published in Clinical Pharmacology and Therapeutics, confirmed that even mild renal impairment (eGFR 60-89 mL/min/1.73m²) increases gabapentin exposure by approximately 20% compared to normal renal function [8]. This matters because many patients seeking AOD-9604 for body composition goals carry metabolic comorbidities (obesity, metabolic syndrome, type 2 diabetes) that independently impair renal function.

The clinical instruction is clear: before combining these agents, obtain a baseline serum creatinine and calculate eGFR. Repeat at 4 to 6 weeks. If eGFR declines, gabapentin dose reduction takes priority.

Dose-Adjustment Guidance

No evidence-based dose-adjustment protocol exists for this specific combination. The following framework draws from general DDI principles and the individual drug profiles.

Gabapentin. Maintain the current dose if renal function is stable (eGFR >60 mL/min/1.73m²). If eGFR is 30-60, follow FDA label reductions (200-700 mg/day in divided doses) [1]. Do not increase the gabapentin dose while initiating AOD-9604.

AOD-9604. Typical compounding doses range from 250 to 500 mcg subcutaneously, administered once daily. Because AOD-9604 is not FDA-approved and lacks formal PK data in renally impaired populations, conservative dosing (starting at the lower end of the range) is appropriate when co-administered with renally cleared medications.

Timing. No data supports a specific dosing interval between the two. A reasonable precaution is to separate administration by 2 to 3 hours to avoid any theoretical interference with absorption, though this is an empiric recommendation rather than an evidence-based one.

Patient Counseling Points

Clinicians prescribing or supervising this combination should address five areas with patients.

Sedation awareness. "Gabapentin can cause drowsiness in about 1 in 5 people. If you notice increased sleepiness, brain fog, or unsteadiness after starting AOD-9604, contact the clinic before your next dose."

Fall risk. Gabapentin-associated ataxia and dizziness increase fall risk, particularly in patients over 65. The CDC's STEADI initiative identifies gabapentin as a fall-risk medication. Adding a second agent with any CNS activity compounds this concern.

Alcohol avoidance. The gabapentin label warns against concurrent alcohol use due to additive CNS depression [1]. This warning extends to any combination that may further lower the CNS depression threshold.

Hydration and renal health. Patients should maintain adequate hydration, report any decrease in urine output, and attend scheduled lab work. Dehydration is common in patients on calorie-restricted protocols alongside AOD-9604 and can precipitate acute kidney injury, which would dramatically increase gabapentin toxicity.

Regulatory transparency. Patients should understand that AOD-9604 is not FDA-approved and has not undergone formal drug interaction testing. The American Medical Association's (AMA) Code of Ethics opinion 2.1.4 underscores the physician's duty to disclose the investigational nature of unapproved therapies, and this duty applies squarely to compounded peptides [9].

Specific Populations Requiring Extra Caution

Three patient groups warrant heightened vigilance when combining AOD-9604 and gabapentin.

Older adults (age >65). Age-related decline in renal function (average GFR decreases approximately 1 mL/min/year after age 40) means gabapentin accumulates more readily. The American Geriatrics Society's 2023 Beers Criteria lists gabapentin as a medication requiring dose adjustment and CNS monitoring in older adults [10].

Patients with obesity and type 2 diabetes. Diabetic nephropathy affects roughly 40% of people with type 2 diabetes according to the National Institute of Diabetes and Digestive and Kidney Diseases. These patients are both the most likely users of AOD-9604 and the most vulnerable to renal accumulation of gabapentin.

Patients on concurrent opioids. The FDA's 2019 gabapentinoid safety communication specifically flagged the combination of gabapentinoids with opioids as a respiratory depression risk [2]. A 2020 nested case-control study by Gomes et al. in PLOS Medicine (N=4,863 cases) found that gabapentin co-prescribed with opioids was associated with a 49% increase in opioid-related mortality (adjusted OR 1.49 to 95% CI 1.18-1.88) [11]. Adding AOD-9604 as a third agent in an opioid-gabapentin regimen introduces additional unknowns into an already high-risk combination.

The Regulatory Gap and What It Means for Safety

AOD-9604 is available through 503A compounding pharmacies under the Federal Food, Drug, and Cosmetic Act's compounding exemptions. It is not listed on the FDA's drug interaction database (DailyMed), is not indexed in the National Library of Medicine's DailyMed repository as an approved product, and has no Risk Evaluation and Mitigation Strategy (REMS).

The FDA's 2023 guidance on bulk drug substances in compounding reminds practitioners that compounded products "are not FDA-approved" and that "there is no FDA finding of safety or effectiveness." This regulatory posture places the interaction-assessment burden entirely on the prescribing clinician.

A 2012 phase IIb trial of oral AOD-9604 (300 mg daily) in 536 obese adults, published by Stier et al. in the Journal of Endocrinology and Metabolism, reported adverse events comparable to placebo over 24 weeks, with no hepatic or renal safety signals [4]. That trial excluded patients on gabapentin and other anticonvulsants, so it provides no direct combination safety data.

Monitoring Protocol for Co-Administration

For clinicians choosing to supervise this combination, a minimum monitoring schedule should include baseline and 6-week labs (comprehensive metabolic panel with eGFR), CNS symptom screening at each follow-up visit (using a standardized dizziness/somnolence scale), patient-reported outcome tracking for gabapentin efficacy (pain or seizure control should not deteriorate after adding AOD-9604), and reassessment of the AOD-9604 indication at 12 weeks. If the peptide has not produced measurable body composition changes by that point, the risk-benefit ratio of continued co-administration favors discontinuation.

Baseline serum creatinine of 1.3 mg/dL or higher (corresponding to eGFR <60 in most adults) should prompt gabapentin dose adjustment before AOD-9604 initiation, not after.